Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials

Schizophr Res. 2011 Mar;126(1-3):212-9. doi: 10.1016/j.schres.2010.10.016. Epub 2010 Nov 9.

Abstract

Background: In randomized controlled trials of antipsychotics, various cutoffs have been used to define response on continuous outcome measures.

Aims: To find a summary effect measure that remains constant across different definitions of response.

Method: We conducted secondary analyses of individual patient data from 10 randomized controlled trials of second-generation antipsychotics for schizophrenia (n=4278) by applying a meta-analytic approach to produce odds ratios (OR), risk ratios (RR) and risk differences (RD) and their 95% confidence intervals (CI) for different definitions of response, using cutoffs of 10% through 90% reduction on the symptom severity rating scales. Constancy of these indices was examined through visual inspection, by way of I-squared statistics to quantify heterogeneity, and by way of coefficients of variation. If any of these indices were found to remain reasonably constant, we next examined the concordance between the number needed to treat (NNT) predicted from them and the observed NNT.

Results: OR and RR remained reasonably constant across various definitions of response, especially for those using thresholds of 10% through 70% reduction. The NNTs predicted from OR and RR agreed well with the observed NNTs, with ANOVA intraclass correlation coefficients of 0.96 (95% CI: 0.92 to 0.98) and 0.86 (0.72 to 0.93), respectively.

Conclusions: The relative measures of treatment effectiveness remain reasonably constant across different scale-derived definitions of response and, in conjunction with varying control event rates, can give accurate estimates of NNTs for individuals with schizophrenia.

Publication types

  • Meta-Analysis

MeSH terms

  • Analysis of Variance
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines / therapeutic use*
  • Female
  • Haloperidol / therapeutic use*
  • Humans
  • Male
  • Olanzapine
  • Predictive Value of Tests
  • Psychiatric Status Rating Scales
  • Randomized Controlled Trials as Topic
  • Schizophrenia / drug therapy*
  • Sensitivity and Specificity
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Benzodiazepines
  • Haloperidol
  • Olanzapine